Phase I/II Study Using Imatinib and s.c. BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia (CML) Patients in First Chronic Phase Achieving Less Than Optimal Response With Imatinib

Trial Profile

Phase I/II Study Using Imatinib and s.c. BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia (CML) Patients in First Chronic Phase Achieving Less Than Optimal Response With Imatinib

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2016

At a glance

  • Drugs BL 8040 (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment due to loss of support
    • 17 Sep 2014 Planned initiation date changed from 1 May 2014 to 1 Dec 2014, as reported in a BioLineRx media release.
    • 06 Aug 2014 According to a BioLineRx media release, this trial is expected by the end of 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top